Icanbelimod
Based on 1 Customer Validation
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.90%
- CAS. Nr.: 1514888-56-2
- Formel: C23H24FN3O3
- Molecular Weight:409.45
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-12355
SiponimodS1P1/S1P5 Agonist -
HY-10968
CYM5442S1P1 Receptor Agonist -
HY-19511
GSK2018682LPL Receptor Agonist -
HY-10569
PonesimodS1P1 Agonist -
HY-12789
EtrasimodS1P1 Receptor Antagonist -
HY-17606
CenerimodS1P1 Agonist -
HY-12288
OzanimodS1P Receptor Modulator -
HY-12685
CeralifimodLPL Receptor Agonist -
HY-13660
Mocravimod hydrochlorideS1PR Regulator -
HY-W008947
SEW2871S1P1 Agonist -
HY-12288A
Ozanimod hydrochlorideS1P Receptor Modulator -
HY-139310
GLPG2938S1P2 Antagonist
Biologische Aktivität
Beschreibung
IC50 & Target
EC50: 9.83 nM (S1P1 internalization)[1]
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats[1]
-
Dosage:3 mg/kg
-
Administration:Oral administration
-
Result:Decreased the severity score of arthritis in the four-legged rats.
-
Animal Model:Female C57BL/6 mice[1]
-
Dosage:0.03, 0.1, and 1 mg/kg
-
Administration:Oral administration
-
Result:Decreased the severity score of EAE in MOG 35-55 induced mice.
Chemical Information
-
CAS. Nr. 1514888-56-2
-
Appearance Solid
-
Molecular Weight 409.45
-
Formel C23H24FN3O3
-
Color White to off-white
-
SMILES
O=C(C1CN(CC2=CC=C(C3=NOC(C4=CC=C(CC(C)C)C=C4)=N3)C=C2F)C1)O
-
Synonyms
S1p receptor agonist 1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 6.8 mg/mL (16.61 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4423 mL | 12.2115 mL | 24.4230 mL | 61.0575 mL |
| 5 mM | 0.4885 mL | 2.4423 mL | 4.8846 mL | 12.2115 mL | |
| 10 mM | 0.2442 mL | 1.2212 mL | 2.4423 mL | 6.1058 mL | |
| 15 mM | 0.1628 mL | 0.8141 mL | 1.6282 mL | 4.0705 mL |
Icanbelimod Related Classifications
HY-101265 Related Classifications
Powered by Bioz